Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
Sponsor: Gannex Pharma Co., Ltd.
Summary
This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).
Official title: A Phase II, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
183
Start Date
2022-09-30
Completion Date
2025-06-10
Last Updated
2025-01-08
Healthy Volunteers
No
Interventions
2mg of ASC41
ASC41 tablet administered orally once daily.
4mg of ASC41 (2 tablets of 2 mg ASC41)
ASC41 tablets administered orally once daily.
Placebo
Placebo tablets administered orally once daily.
Locations (1)
The affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China